NASDAQ · Drug Manufacturers - Specialty & Generic

Viatris Inc. (VTRS) Stock

$18.00 -2.60% NASDAQ: VTRS Healthcare

Valuation

MetricValue
Price$18.00
Market Cap$20.67B
P/E Ratio-50.33
P/B Ratio1.48
P/S Ratio1.43
EPS (TTM)$-0.30
52-Week High$18.67
52-Week Low$9.55
Dividend Yield2.65%

Financials & Margins

MetricValue
ROE-2.79%
ROA-1.17%
ROCE-0.30%
Gross Margin39.82%
Operating Margin6.78%
Net Margin-2.79%
Debt/Equity0.96
Current Ratio1.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$17.9B$16.3B$15.4B$14.7B$14.3B
Operating Profit$-34.0M$1.6B$766.0M$10.0M$-2.7B
Net Profit$-1.3B$2.1B$55.0M$-634.0M$-3.5B
EPS$-1.05$1.71$0.05$-0.53$-3.00
Op Margin-0.2%9.9%5.0%0.1%-18.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$54.8B$50.0B$47.7B$41.5B$37.2B
Total Liabilities$34.4B$28.9B$27.2B$22.9B$22.5B
Cash$701.0M$1.3B$992.0M$735.0M$1.3B
Borrowings$23.4B$19.5B$18.4B$14.3B$14.7B

Latest News

VTRS or DHR: Which Is the Better Value Stock Right Now? Zacks · Jul 9, 2026 Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight PR Newswire · Jul 9, 2026 Should Value Investors Buy Viatris (VTRS) Stock? Zacks · Jul 9, 2026 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now 24/7 Wall St. · Jul 7, 2026 Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move? Simply Wall St. · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$3.0B$3.0B$2.8B$2.3B$2.3B
Investing Cash Flow$-627.0M$985.0M$-1.2B$1.5B$-806.0M
Financing Cash Flow$-514.0M$-19.0M$-480.0M$-44.0M$-735.0M
Net Cash Flow$-144.0M$556.0M$-269.0M$-257.0M$612.0M
Free Cash Flow$2.5B$2.5B$2.3B$2.0B$1.9B

Valuation & Return Ratios

MetricValue
PEG Ratio-3.45
EV / EBITDA12.81
FCF Yield8.88%
Quick Ratio0.96
Interest Coverage-0.18
Return 1Y80.78%
Return 3Y124.12%
Return 5Y61.07%

Ownership

Insiders Held0.31%
Institutions Held88.26%
Institutions Float Held88.54%
Institutional HolderSharesReport Date
Blackrock Inc.84,359,8042026-03-31
Davis Selected Advisers78,211,1912026-03-31
Vanguard Capital Management LLC74,716,6312026-03-31
Price (T.Rowe) Associates Inc65,864,1042026-03-31
Vanguard Portfolio Management LLC53,911,2372026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALKSAlkermes plc $43.63 -1.24% 103.60 $7.32B 0.00%
AMPHAmphastar Pharmaceuticals, Inc. $25.14 -3.46% 14.50 $1.07B 0.00%
AMRXAmneal Pharmaceuticals, Inc. $20.38 -0.49% 38.55 $6.51B 0.00%
ANIPANI Pharmaceuticals, Inc. $72.61 -1.55% 14.94 $1.67B 0.00%
BHCBausch Health Companies Inc. $6.44 -0.77% -2.00 $2.41B 0.00%

About Viatris Inc.

Viatris Inc. is led by CEO Scott Andrew Smith, employs 30,000 people, headquartered in Canonsburg, US, publicly traded since 1980.

Viatris Inc. (VTRS) stock trades at $18.00 with a market capitalization of $20.67B. The stock is valued at a negative price-to-earnings (P/E) ratio of -50.33, reflecting a net loss over the last twelve months, price-to-book of 1.48, price-to-sales of 1.43. Over the past 52 weeks the stock has ranged between $9.55 and $18.67, and currently trades 3.6% below its 52-week high. It pays a dividend yielding 2.65%.

On profitability, Viatris Inc. generates a return on equity (ROE) of -2.79% (negative, reflecting a net loss), return on capital employed of -0.30%, an operating margin of 6.78%, a net profit margin of -2.79%.

In its most recent fiscal year, Viatris Inc. reported annual revenue of $14.3B, a net loss of $3.5B. Revenue grew at an average annual rate of 3.7% over the last 5 fiscal years.

The balance sheet shows a debt-to-equity ratio of 0.96, a current ratio of 1.60, total assets of $37.2B, $1.3B in cash and equivalents.

VTRS has an average daily trading volume of 9,523,555 shares, a beta of 0.88.

Viatris Inc. by the numbers, 2016–2025

Between 2016 and 2025 Viatris Inc. reported revenue of $11.1B rising to $14.3B, a change of +29.1% across 10 years. Compounded, revenue has grown 3.7% a year over five years, -4.2% over three, -3.0% over the last twelve months. Net profit fell to $-3.5B.

Operating margin went from 6.3% in 2016 to -18.6% in 2025, a fall of 24.9 percentage points. The most recent net margin is -2.79%. On a trailing twelve-month basis to Jun '26, revenue is $14.7B and net profit $-411.0M.

Borrowings fell from $15.5B to $14.7B, cash from operations was $2.3B in the latest year, positive in 10 of the last 10.

Return on equity has averaged -4.7% over five years, and was -23.9% in the most recent year.

The share price itself has compounded at 5.9% a year over five years, 28.4% over three, 100.6% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Viatris Inc. (VTRS) — frequently asked questions

What is Viatris Inc. (VTRS) stock price today?

Viatris Inc. (VTRS) is currently trading at $18.00, down 2.6% today.

What is VTRS P/E ratio?

Viatris Inc.'s P/E ratio is -50.33. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is VTRS return on equity (ROE)?

Viatris Inc.'s return on equity (ROE) is -2.79%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Viatris Inc.'s market cap?

Viatris Inc. has a market capitalization of $20.67B.

Does VTRS pay a dividend?

Yes. Viatris Inc. currently yields 2.65%. Yield moves with the share price, so it changes daily even when the payment does not.

How much debt does VTRS carry?

Viatris Inc. has a debt-to-equity ratio of 0.96. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is VTRS's profit margin?

Viatris Inc. reports a net profit margin of -2.79% — the share of revenue left after every cost, including tax and interest.

What sector is VTRS in?

Viatris Inc. is classified under Healthcare, in the Drug Manufacturers - Specialty & Generic industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is VTRS listed on?

Viatris Inc. trades on NASDAQ under the ticker VTRS.

What is VTRS's 52-week range?

Over the last year Viatris Inc. has traded between $9.55 and $18.67.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens VTRS currently matches

On the figures above, Viatris Inc. passes the filters for 7 of our ready-made screens, among them Dividend Stocks, S&P 500 Dividend Stocks, Large Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Dividend StocksS&P 500 Dividend StocksLarge Cap StocksStocks Under $100Stocks Under $50Large Cap Dividend StocksDebt to Equity Below 1 Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.